Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

Survival update and prognostic factor analysis of oxaliplatin (ox) and irinotecan (iri) combinations in patients with metastatic colorectal cancer (MCRC).

    -- An updated analysis of the phase III N9741 study evaluating FOLFOX4

       versus irinotecan-based chemotherapy in metastatic colorectal cancer

       patients will be presented.

    -- Monday, June 4, 8:00 AM - 12:00 PM, S Hall A2, Poster Presentation.

Abstract # LBA5 - Final results of the EORTC Intergroup randomized phase III study 40983: Peri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer.

    -- The study examines the use of chemotherapy with oxaliplatin/5FU/LV

       (FOLFOX4) given before and after surgery of liver metastases from

       metastatic colorectal cancer versus surgery alone.  Eloxatin(R) for

       peri-operative use is not in the U.S. label.

    -- Monday, June 4, 3:30 PM - 3:45 PM, N Hall B1, Plenary Session.

For information about currently approved uses of Eloxatin(R), please see full prescribing information.

Taxotere(R) (docetaxel) Injection Concentrate clinical studies:

Abstract # LBA1008 - BCIRG007: First overall survival analysis of a randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC).

    -- This study evaluates the use of two Taxotere(R) - Herceptin

       (trastuzumab) regimens for the treatment of metastatic HER2 positive

       breast cancer patients.

    -- Sunday, June 3, 9:45 AM - 10:00 AM, N Hall B1, Oral Presentation.

Abstract #537 - Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3490 patients included in two randomized trials.

    -- This presentation reviews the use of Taxotere(R) in trials involving

       patients with early stage node positive breast cancer, accor
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:2/27/2015)... , Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the ... company, today announced financial results for its first quarter ... three months ended December 31, 2014, revenue was $1,336,685. ... was $229,820 or $0.02 per share.  ... "I am very pleased with the significant progress we ...
(Date:2/27/2015)... February 27, 2015 ... Überwachungssystem für kongestive Herzinsuffizienz (CHF) in seiner ...     Die ... neuartiges Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz ... sie ein Finanzierungsvorhaben über 5 Mio. USD ...
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... A new HIV antigen-antibody,combination assay, currently available in Europe, ... with acute HIV infection, who would,be missed by traditional ... Hopkins University , Abbott ( NYSE: ABT ... Opportunistic Infections (CROI). , "Those ...
... 6 The U.S. Agency for International ... of Zimbabwe, who are in the midst of an ... the cholera epidemic have left the people of Zimbabwe ... the President,s Malaria Initiative, is supporting emergency Indoor Residual ...
Cached Medicine Technology:Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening 2Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening 3Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening 4USAID Provides Malaria Assistance to Zimbabwe 2
(Date:2/28/2015)... For those people who are unable to ... Applied Research Foundation (Meso Foundation) will broadcast its ... at 9:30 AM. , The live broadcast is free ... be accessed through any browser on a computer or ... is a unique event that covers important treatment information ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 A ... federal testosterone lawsuits that have been filed by law ... the second week in March, the Firm notes. ... website, parties involved in the federal litigation will meet ... matters related to prescription therapy treatments designed to raise ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 On Thursday, February ... Make It Easy For Scammers To Steal Your Data , ... get their hands on a DIY phishing kit, or any ... also touched on another important point about how everyone’s cyber ... are often implemented, “like compromising legitimate content management systems or ...
(Date:2/28/2015)... February 28, 2015 Developers of FCPX ... a new overlay plugin for Final Cut Pro X entitled ... “FCPX Overlay Chromatic gives users total control over 6k lens ... CEO of Pixel Film Studios. “FCPX Overlay Chromatic was professionally ... to use interface.” , FCPX Overlay Chromatic Grunge 6K is ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2
... hay fever symptoms could be reduced by 60% with the ... in Baltimore. ,Dr. Peter Socrates Creticos, medical director ... Johns Hopkins University School of Medicine and his team tested ... ,The study was conducted on 25 volunteers with ...
... health shops to overcome depression only one actually has any ... have said that St John's Wort is the only alternative ... others including gingko biloba, ginseng, cat's claw, royal jelly and ... serious drug interactions". ,The experts, Joyce Reed, a ...
... a dozen top universities on Tuesday by the government ... hasten scientific discoveries towards better health care thereby trying ... ,This idea came about because of the increased specialization ... ever for scientists from different fields to share the ...
... the All India Institute of Medical Sciences (AIIMS), including ... postponed its medical students' semester examination scheduled for later ... their hostel rooms after a seventh semester student died ... virus include medical students, resident doctors and other hospital ...
... and biotech major Wockhardt Limited announced on Tuesday ... $150 million that will help it broaden its presence ... a larger footprint in Europe spread over Britain, Ireland ... ,'European business will now exceed $200 million, accounting for ...
... tuberculosis that caused a major outbreak in a British school ... has surfaced again, directing its destruction on a specific ethnic ... a study to examine the potency of the 2001 outbreak. ... disease with the BCG vaccine. ,The severe strain, ...
Cached Medicine News:Health News:DNA vaccine for ragweed allergies 2Health News:Unscientific Depression Drugs aplenty in Health Stores 2Health News:NIH Funds the Development of National Consortium of Universities 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
Medicine Products: